Pharmacists take on heart disease: new study tests community-based risk reduction
NCT ID NCT06405880
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle changes. The goal is to see if this approach lowers cardiovascular risk more than usual care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pharmacist-led care pathway
- What this could lead to
- If successful, this could show that pharmacist-led programs effectively reduce heart disease risk in the community.
- What could go wrong
- This is an implementation study, not a drug trial. Results depend on real-world adherence and may not apply to all settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Alberta
Edmonton, Alberta, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Can a Two-Drug combo tip the scales against obesity?
- Aging kidneys under the microscope: could a simple test predict failure?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation